ITGAX and systemic lupus erythematosus: Our work thus describes a targeted pharmacological approach for the elimination of pathogenic CD11c+T-bet+ B cells and highlights the therapeutic potential of A2A receptor agonists in the treatment of SLE, and possibly other autoimmune diseases.